Finance
Merck CEO on disintermediation in pharma
- Merck CEO Kenneth Frazier thinks something has to change within the pharmaceutical industry to fix the issue of drug pricing.
- “I don’t understand where we live in a world where 50% of the value goes to the supply chain,” Frazier said at an event at the Economic Club of New York last week.
- Frazier said he expects to see disintermediation — or reducing the number of companies between a product and a consumer — start to happen in the pharmaceutical industry, in the way it’s happened with cable.
As Kenneth Frazier sees it, something has to give.
During an hour-long, wide-ranging interview with the Economic Club of New York, Frazier, the CEO of New Jersey-based pharma giant Merck, addressed the issue of rising prescription drug costs and how it’s impacting patients.
The way he sees it, Merck publishes the list prices the company sets for a particular drug. The list price is the amount a drugmaker sets, and it’s often the most publicly available number. But after that’s set, there are often discounts the drugmaker pays out to middlemen, which may or may not make their way directly to patients. Those discounts vary and are kept secret. And if you have a high deductible plan, you might still be on the hook for paying the full list price, even if you don’t get the direct benefit of the discounts.
For example, Merck has published reports outlining the company’s average list and net price increases for its products. Merck’s average net prices after factoring in those discounts decreased by 1.9% in 2017 as list prices increased 6.6%.
“I don’t understand where we live in a world where 50% of the value goes to the supply chain,” Frazier said.
Frazier said he expects to see disintermediation — or reducing the number of companies between a product and a consumer — start to happen in the pharmaceutical industry, in the way it’s happened with cable. Before Disney owned its own media networks, it had to pay to get its content in front of viewers. Now, it owns media networks like ABC and ESPN, which it can use to show its content, making it one less step to get to viewers.
The same could happen in the pharmaceutical industry. Already, mergers are taking place that combine insurers with pharmacy benefit managers, the middlemen responsible for negotiating discounts to the list price of medications on behalf of health plans and insurers. And the Trump administration has been putting pressure on the PBMs and the rebates they receive from drugmakers. Whether those changes lead to less drug pricing pressure remains to be seen.
“I know how hard it is to make my 50 cents on the dollar,” Frazier said. “I think that system’s got to change.”
See more:
-
Business7 days ago
Consumer Financial Protection Bureau fines BloomTech for false claims
-
Business5 days ago
Langdock raises $3M with General Catalyst to help businesses avoid vendor lock-in with LLMs
-
Entertainment5 days ago
What Robert Durst did: Everything to know ahead of ‘The Jinx: Part 2’
-
Entertainment4 days ago
This nova is on the verge of exploding. You could see it any day now.
-
Business4 days ago
India’s election overshadowed by the rise of online misinformation
-
Business4 days ago
This camera trades pictures for AI poetry
-
Business5 days ago
CesiumAstro claims former exec spilled trade secrets to upstart competitor AnySignal
-
Business6 days ago
Screen Skinz raises $1.5 million seed to create custom screen protectors